1.Determination of Chromium (Ⅵ) in Waste Water by Inductively Coupled Plasma-Atomic Emission Spectrometry
Nanning SHI ; Jianxin ZHANG ; Luosheng XU
Journal of Environment and Health 1993;0(03):-
ve To study the new method for determination of chromium (Ⅵ) in waste water. Methods The chromium (Ⅵ) from waste water samples was seperated by ion-exchange method and concentrated, then was analyzed by inductively coupled plasma-atomic emission spectrometry. Results The precision, average recovery rate and detection limit were 2.05%, 99.7% and 0.018?g/ml respectively. Conclusion This method was easy and rapid to operate, and revealed less interference in determination of chromium (Ⅵ) in industrial waste water.
2.Studies on determination of ferulic acid by HPLC
Luosheng HUANG ; Jianxin GUO ; Yongmei LIU ; Junying ZHANG ; Qineng PING ;
Chinese Traditional Patent Medicine 1992;0(02):-
AIM: The purpose is to study the stability of ferulic acid and develop a method for determining the content of ferulic acid in angelica sinensis by HPLC. METHODS: The solvent of reference ferulic acid was HCOOH H 2O(5∶95), but the solvent of the sample was HCCOH CH 3OH(5∶95). The separation was performed on Shimpack CLC -ODS column with acetonitrile (containing 0.2% methanol) 0.1% triethylamine (containing 0.1% phosphate)(20∶80) as mobile phase. Ferulic acid was detected at 324nm with flowing rate as 1.0mL?min -1 . RESULTS: The calibration curve was linear ( r =0.9998) in the range of 0.704 17.6 ?g?mL -1 for ferulic acid. The average recovery was 99.33% and RSD 0.60%, respectively. CONCLUSION: The method is quick and convenient for determination of ferulic acid.
3.Development and clinical application of integrated network management platform for tumor radiotherapy information
Xingwang GAO ; Guangshun ZHANG ; Li CHEN ; Luosheng ZHANG ; Shaomin HUANG ; Xiaowu DENG
Chinese Journal of Radiation Oncology 2016;25(4):395-400
Objective To develop a network management system for tumor radiotherapy information that integrates process management and quality assurance functions, and to investigate its clinical value. Methods Based on the requirements of radiotherapy process quality assurance and control, the client-server ( C-S) pattern, along with SQL SERVER 2008 database structure, international standard DICOM 3.0, DICOM RT, and HL7 protocols, and system hardware and self-developed software in local area network, was adopted to establish the network management system for radiotherapy information, and clinical tests were performed to evaluate the operation performance of this platform.Results ( 1 ) The interactive integrated management platform and client-side functional modules with a uniform interface were developed.( 2) The safe and reliable standardized data interface was developed, which could be connected to accelerators, treatment planning systems, and hospital information systems developed by mainstream manufacturers.( 3) The modules for radiotherapy process management and quality assurance and management were designed and developed.( 4) The platform passed all the tests before operation and had been used in clinical departments for almost 3 years, which confirmed that the system was safe and stable during operation and that all functions designed were realized.Conclusions The integrated management platform meets the requirements for application and management of radiotherapy information and data, improves the overall work efficiency in radiotherapy department and the level of quality assurance and control, and holds promise for clinical application as a good tool for tumor radiotherapy departments.
4.Role of Notch signaling in differentiation of retinal progenitor cells.
Kun ZHANG ; Guangxiu LU ; Ling GAO ; Luosheng TANG ; Jian WANG ; Tao WANG ; Rong HU
Journal of Central South University(Medical Sciences) 2009;34(6):492-497
OBJECTIVE:
To investigate the role of Notch signaling in differentiation of Sprague-Dawley (SD) rat retinal progenitor cells (RPCs).
METHODS:
RPCs were isolated from 16-day embryonic SD rats and cultured in suspension. RPCs were cultured respectively in media with (treatment group) or without (control group) gamma-secretase inhibitor X which was used to block Notch signaling. Morphological observation and immunocytochemistry were applied at day 14 to determine the cell types and analyze the expression of Notch pathway genes in both groups.
RESULTS:
Most RPCs expressed Notch1 intracellular domains or its downstream transcriptional factor Hes1. A few expressed bHLH transcriptional factors NeuroD and Mash1. Most auto-differentiated RPCs expressed NeuroD or Mash1, while a few of them expressed Notch1 intracellular domains or Hes1. In the group treated with gamma-secretase inhibitor X, the positive rate of Nestin or GFAP was much lower than that in the control group while the positive rate of beta-tubulin was much higher than that in the control group. The difference in the positive rate of recovering between the two groups was not significant.
CONCLUSION
In vitro Notch signaling may inhibit retinal stem cells differentiation. Inhibiting Notch signaling in vitro may promote differentiation to neurons and partially inhibit glial differentiation.
Animals
;
Basic Helix-Loop-Helix Transcription Factors
;
metabolism
;
Cell Differentiation
;
physiology
;
Cells, Cultured
;
Female
;
Fetus
;
Homeodomain Proteins
;
metabolism
;
Neurons
;
cytology
;
Rats
;
Rats, Sprague-Dawley
;
Receptor, Notch1
;
genetics
;
metabolism
;
Retina
;
cytology
;
Signal Transduction
;
drug effects
;
physiology
;
Stem Cells
;
cytology
;
Transcription Factor HES-1
5.Research progress of measurement tools for health-related quality of life in patients with spinal metastases
Mengchen YIN ; Wenlong YU ; Lin LI ; Xin GAO ; Luosheng ZHANG ; Dingbang CHEN ; Quan HUANG ; Xinghai YANG ; Junming MA ; Jianru XIAO ; Wen MO
Chinese Journal of Orthopaedics 2023;43(16):1115-1122
The Health-Related Quality of Life (HRQoL) pertains to patients' subjective contentment concerning their physical, psychological, and social well-being throughout disease treatments. Predominantly employed HRQoL metrics in spinal metastases comprise the 36-item Short-Form Health Survey (SF-36), EuroQoL Five Dimensions Questionnaire (EQ-5D), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and the Functional Assessment of Cancer Therapy-General (FACT-G). In clinical applications, due to their broad application and diverse disease types, combined with the lack of specificity in the scale content and the prolixity of their questionnaires, these tools often fail to capture the nuanced experiences of patients, thereby compromising the reliability and validity of the results. The Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ), developed by the Spine Oncology Study Group, offers a tailored metric for spinal metastases, encapsulating both specificity and inclusivity. Its proven robust reliability and validity make it invaluable for decision-making and therapeutic efficacy appraisals. The Patient-Reported Outcome Measurement Information System (PROMIS), a novel metric suitable across many medical disciplines, facilitates cross-sector data acquisition, substantially augmenting the precision, sensitivity, and credibilityof assessments, and is pivotal in clinical investigations and interventions. As it continually evolves, PROMIS consistently outperforms traditional metrics in evaluative capacities, exhibiting impressive and consistent proficiency in prognostications, preoperative assessments, and therapeutic outcome evaluations within the spinal metastasis domain. Presently, Chinese research on the HRQoL of spinal metastasis patients remains scant, and choosing an apt, precise, and dependable metric holds significant clinical relevance. Drawing upon extant scholarly publications, this review concluded the current global HRQoL tools for spinal metastases, aiming to furnish insights for the clinical management and research pertaining to spinal metastases.